medigraphic.com
ISSN 1405-1710 (Impreso)

2003, Número 1

<< Anterior Siguiente >>

Rev Cent Dermatol Pascua 2003; 12 (1)


Pimecrolimus, opción terapéutica

Alvarado DA, Beirana PA

Idioma: Español
Referencias bibliográficas: 53
Paginas: 7-14
Archivo PDF: 79.60 Kb.


RESUMEN

El pimecrolimus es un inhibidor selectivo de la liberación inflamatoria de las citocinas, desarrollado específicamente para el tratamiento de enfermedades inflamatorias de la piel. Se realiza una revisión acerca de pimecrolimus, indicaciones y tolerabilidad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia with atopic eczema. Br J Dermatol 2000; 142: 931-936.

  2. Van Leent EJ, Ebelin ME, Burtin P et al. Low systemic exposure after repeated topical applications of pimecrolimus (Elidel, SDZ ASM 981) in patients with atopic dermatitis. Dermatology 2002; 204(1): 63-8.

  3. Ortiz de Frutos FJ. New alternatives in atopic dermatitis treatment. Allergol Immunopathol 2002; 30(3): 134-40.

  4. Hebert AA, Warken KA, Cherill R. Pimecrolimus cream 1%: a new development in nonsteroid topical treatment of inflammatory skin diseases. Semin Cutan Med Surg 2001; 20(4): 260-7.

  5. Wellington K, Jarvis B, Topical pimecrolimus. A review of its clinical potential in the management of atopic dermatitis. Drugs 2002; (5): 817-840.

  6. Stuetz A, Grassberger M, Josef G et al. Preclinical pharmacologic profile and skin selectivity. Seminars in cutaneous Medicine and Surgery 2001; 20(4): 233-241.

  7. Monografía de producto. Elidel (pimecrolimus) crema al 1%. Novartis. Julio 2002.

  8. Lakhanpaul M, Allen BR, Wahn U et al. Pimecrolimus cream 1%: minimal systemic absorption in infants with extensive atopic eczema. Abstract no. 48 (plus poster) in The IX World Congress of Pediatric Dermatology, Cancún, Méx. 2001.

  9. Harper J, Green A, Allen R et al. Pimecrolimus cream 1% consistently low blood concentrations in children with extensive atopic eczema. Abstract no. 49 (plus poster) in the IX World Congress of Pediatric Dermatology, Cancún, Méx. 2001.

  10. Harper J, Lakhanpaul M, Wahn U et-al. Pimecrolimus cream 1%. Blood levels are consistently low in children with extensive atopic eczema. (plus poster) in The 10th Congress of the European Academic of Dermatology and Venereology (EADV) Munich, Germany 2001.

  11. Van Leent EJ, DeVries H, Scott G et-al. Low blood concentrations of pimecrolimus after topical treatment of adults with atopic eczema. (P2-8 plus poster) in The 10th Congress of the European Academic of Dermatology and Venereology (EADV) Munich, Germany 2001.

  12. Harper J, Green A, Scot G et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin disease: in vivo pharmacology. Br J Dermatol 1997; 137: 568-76.

  13. Thaci D, Kaufmann R, Scott G et al. Consistently low blood levels of pimecrolimus (SDZ ASM 981) after occlusive topical treatment of chronic hand eczema. (P17-8 plus poster) In: The 10th Congress of the European Academic of Dermatology and Venereology (EADV) Munich, Germany 2001.

  14. Greig G, Burtin P, Scott G. Oral SDZ ASM 981 pharmacokinetic profile in humans. (abstract No. 513) 59th AAD 2001; Summary in 2 part ( part A).

  15. Zuberbier T, Chong SU, Grunow K et al. The ascomycin macrolactam pimecrolimus (Elidel SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cell and peripheral blood basophils. J Allergy Clin Immunol 2001; 108: 275-80.

  16. Grassberger M, Baumruker T, Enz A et al. A novel anti-inflammatory drug. SDZ AMZ 891 for the treatment of skin diseases. In vitro pharmacology. Br J Dermatol 1999; 141: 264-73.

  17. Paul C, Ho V. Ascomycins in Dermatology. Semin Cutan Med Surg 1998; 17(4): 256-259.

  18. Manome H, Aiba S, Yoshino Y. Altered cytokine production and expression of costimulatory molecules in monocytes and monocyte-derived dendritic cell from atopic dermatitis patients. (abstracts 440) J Inv Dermatol 2001; 117(2): 463.

  19. Hultsch T, Müller KD, Meingassner JG et al. Ascomycin macrolactam derivate SDZ ASM 981 inhibits the release of granule-associate mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res 1998; 290: 501-7.

  20. Kulthoff E, Chung J, Grassberber M et al. SDZ ASM 981 potently inhibits the induction of correceptors involved in the accessory cell-dependent activation of inflammation mediating T cells. J Invest Dermatol 2001; 117(2): 440.

  21. Kalthoff FS, Chung J, Grassberger M. Pimecrolimus (SDZ ASM 981) potently inhibits co-receptor involved in the activation of inflammatory effector T cells. (P20-24 plus poster) in The 10th Congress of the European Academic of Dermatology and Venereology (EADV) Munich, Germany 2001.

  22. Meingassner JG, Grassberger M, Fahinggruber H et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997; 37: 568-76.

  23. Meingassner JG, Di Padova F, Hiestand P et al. Pimecrolimus in contrast to cyclosporin A and tacrolimus, is highly effective in animal models of skin inflammation but has only low activity in models indicating systemic immunosuppressive potential. Abstract no. 43 (plus poster) in the IX World congress of Pediatric Dermatology, Cancún, Méx. 2001.

  24. Meingassner JG, Stütz A. Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases. J Invest Dermatol 1992; 98: 851-5.

  25. Meingassnner J, Hiestand P, Bigout M et al. SDZ ASM 981 is highly effective in animal models of skin inflammation, but has only low activity in models indicating immunosuppressive potential, in contrast to cyclosporin A and FK506. J Invest Dermatol 2001; 117(2): 532 (abstract 858).

  26. Meingassner JG, Di Padova F, Hiestand P et al. Pimecrolimus: highly effective in models of skin inflammation but low activity in models of immunosupression. (plus poster) in The 10th Congress of the European Academic of Dermatology and Venereology (EADV) Munich, Germany 2001.

  27. Neckermann G, Bavandi A, Meingassner JG et al. Atopic Dermatitis-like symptoms in hipomagnesaemic hairless rats are prevented and inhibits by systemic or topical SDZ ASM 981. Br J of Dermatol 2000; 142: 669-679.

  28. Roussel QC, Duteil PC. The new topical ascomycin derivatives SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001; 144: 507-513.

  29. Ebelin ME, SpaKe A, Heinnih Y et al. Good skin tolerability of SDZ ASM 981 cream. J Eur Acad Dermatol Venereol 1998; 11(Suppl 2): S270.

  30. Laurence F, Eichenfield MD, Lucky AW. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46(4): 495-504.

  31. Meingassner JG, Baumann K, Grassberger M. Topical activity of the immunosuppressive macrolide SDZ 281-240 in animal models of allergic contact dermatitis. J Invest Dermatol 1994; 102: 599.

  32. Queille-Roussel C, Graeber M, Thurston M. SDZ ASM 981 is the first non-steroid that suppresses stablished nickel contact dermatitis elidited by allergen challenge. Contact Dermatitis 2000; 42: 349-50.

  33. Mrowietz U, Graeber M, Brantigam M et al. The novel ascomycin derivate SDZ ASM 981 is effective for psoriasis when used topically under occlussion. Br J Dermatol 1998; 139: 992-996.

  34. Rappersberger K, Komar M, Ebelin ME et al. Oral SDZ ASM 981: safety pharmacokinetics and efficacy in patients with moderate to severe chronic plaque psoriasis. J Invest Dermatol 2000; 114: 776.

  35. Mrowietz U, Wustlich S, Hoexter G et al. Pimecrolimus ointment is effective in psoriasis without occlusion. (Plus poster) in The 10th Congress of the European Academic of Dermatology and Venereology (EADV) Munich, Germany 2001.

  36. Rappersberger K, Richter L et al. Skin biopsy analysis of psoriasis patients treated with pimecrolimus confirms reversal to normal phenotype. (P24-23 plus poster) in The 10th Congress of the European Academic of Dermatology and Venereology (EADV) Munich, Germany 2001.

  37. Paul C, Graeber M. Ascomycins: promising agents for the treatment of inflammatory skin diseases. Exp Opin Invest Drugs 2000; 9 (1): 69-77.

  38. Hanfin JM, Thurson M, Omoto M et al. The EASI evaluator group. The eczema area and severity index ( EASI) assessment of reliability in atopic dermatitis. Exp Dermatol 2001; 10: 11-8.

  39. William HC, Burney PG, Pembroke AC et al. The UK working party’s diagnostic criteria for atopic dermatitis. III Independent hospital validations. Br J Dermatol 1994; 131: 406-16.

  40. Kpaap A, Ho V, Halbert A et al. Pimecrolimus (Elidel, SDZ ASM 981) cream 1% is effective and safe in infants aged 3-23 months with atopic eczema. Abstract No. 45 (plus poster) in The IX World Congress of Pediatric Dermatology, Cancún, Méx. 2001.

  41. Kang S, Lucky A, Pariser D et al. A long-term, noncomparative trial to evaluate the safety of topically applied Tacrolimus as treatment of atopic dermatitis in pediatric patients. (P 110 plus poster) The American Academy of Dermatology 58th Annual Meeting, San Francisco, CA, 2000.

  42. Ho V, Hedgecock S, Bush C et al. SDZ ASM 981 cream 1% is efficacious and safe in infants aged 3-23 months with atopic dermatitis. J Invest Dermatol 2001; 117(2) 532 (abstracts 853).

  43. Kpaap A, Kapp A, Bingham et al. Pimecrolimus cream 1% a new approach to long term management of atopic eczema in infants 3-23 months of age. Abstract No. 47 (plus poster) in The IX World Congress of Pediatric Dermatology, Cancún, Méx. 2001.

  44. Boguniewicz M, Zichenfield L, Honig P et al. Pimecrolimus cream 1% is safe in long term use in pediatrics atopic eczema. Abstract No. 44 (plus poster) in The IX World Congress of Pediatric Dermatology, Cancún, Méx. 2001.

  45. De Prost Y, Wahn U. Pimecrolimus cream 1% provides safe and effective long term management of atopic eczema in children in a 12 month controlled study reducing the need for topical corticosteroid usage. Abstract No. 42 (plus poster) in The IX World Congress of Pediatric Dermatology, Cancún, Méx. 2001.

  46. De Prost Y, Wahn U. Pimecrolimus cream 1% reduces the need for topical corticosteroids to treat atopic eczema in children. (P2-13 plus poster) in The 10th Congress of the European Academic of Dermatology and Venereology (EADV) Munich, Germany 2001.

  47. Wahn U, Molloy S, Graeber M et al. SDZ ASM 981 cream 1% a new approach to long term management of atopic dermatitis. J Invest Dermatol 2001; 117(2): 533.

  48. Whalley D, Mckenna S, Huels J et al. The benefit of pimecrolimus on quality of life in the treatment of pediatric atopic eczema: result of two 6 week randomized double-blind, vehicle-controlled clinical trials in the USA. Abstract no. 46 (plus poster) in The IX World Congress of Pediatric Dermatology, Cancún, Méx. 2001.

  49. Van Leent EJM, Graeber M, Thurson M et al. Effectiveness of the ascomycin macrolactam SDZ AMS 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998; 134: 805-9.

  50. Luger T, Van Leent EJM, Groeber M et al. SDZ ASM 981: an emerging safe and affective treatment for atopic dermatitis. Br J Dermatol 2001; 144: 788-94.

  51. Boguniewicz M, Eichenfield, Honing P. Pimecrolimus cream 1% is safe in the long term management of atopic eczema. Abstract No. P2-12 (plus poster) in The 10th Congress of the European Academic of Dermatology and Venereology (EADV) Munich, Germany 2001.

  52. Novartis Pharma GmbH. Elidel (pimecrolimus) cream 1% prescribing information (on line) Available from URL: http:// www.pharma.us.

  53. novartis.com/product/pi/pdf/elidel. Pdf.




2020     |     www.medigraphic.com